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Abstract
Background: Fifty percent of patients with muscle–invasive bladder cancer (MI-BC) die from their disease and current
chemotherapy treatment only marginally increases survival. Novel therapies targeting receptor tyrosine kinases or activated
oncogenes may improve outcome. Hence, it is necessary to stratify patients based on mutations in relevant oncogenes.
Patients with non-muscle-invasive bladder cancer (NMI-BC) have excellent survival, however two-thirds develop recurrences.
Tumor specific mutations can be used to detect recurrences in urine assays, presenting a more patient-friendly diagnostic
procedure than cystoscopy.
Methodology/Principal Findings: To address these issues, we developed a mutation assay for the simultaneous detection
of 19 possible mutations in the HRAS, KRAS, and NRAS genes. With this assay and mutation assays for the FGFR3 and PIK3CA
oncogenes, we screened primary bladder tumors of 257 patients and 184 recurrences from 54 patients. Additionally, in
primary tumors p53 expression was obtained by immunohistochemistry. Of primary tumors 64% were mutant for FGFR3,
11% for RAS, 24% for PIK3CA, and 26% for p53. FGFR3 mutations were mutually exclusive with RASmutations (p = 0.001) and
co-occurred with PIK3CA mutations (p= 0.016). P53 overexpression was mutually exclusive with PIK3CA and FGFR3
mutations (p#0.029). Mutations in the RAS and PIK3CA genes were not predictors for recurrence-free, progression-free and
disease-specific survival. In patients presenting with NMI-BC grade 3 and MI-BC, 33 and 36% of the primary tumors were
mutant. In patients with low-grade NMI-BC, 88% of the primary tumors carried a mutation and 88% of the recurrences were
mutant.
Conclusions/Significance: The mutation assays present a companion diagnostic to define patients for targeted therapies. In
addition, the assays are a potential biomarker to detect recurrences during surveillance. We showed that 88% of patients
presenting with low-grade NMI-BC are eligible for such a follow-up. This may contribute to a reduction in the number of
cystoscopical examinations.
Citation: Kompier LC, Lurkin I, van der Aa MNM, van Rhijn BWG, van der Kwast TH, et al. (2010) FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer
and Their Potential as Biomarkers for Surveillance and Therapy. PLoS ONE 5(11): e13821. doi:10.1371/journal.pone.0013821
Editor: Venugopalan Cheriyath, Cleveland Clinic, United States of America
Received July 18, 2010; Accepted October 13, 2010; Published November 3, 2010
Copyright:  2010 Kompier et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by an Erasmus MC Breedtestrategie Grant (2002-2006) and The Netherlands Organization for Health Research and
Development (ZON-MW, 945-02-046). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: e.zwarthoff@erasmusmc.nl
Introduction
Bladder cancer is the fifth most common cancer in the Western
World [1]. Of the bladder tumors 15–20% presents as muscle-
invasive disease (MI-BC), the remaining group as non-muscle-
invasive tumors (NMI-BC). MI-BC is a devastating disease since over
50% of the patients will die from metastatic disease. Recently, new
developments in targeted therapies using receptor tyrosine kinase
inhibitors in other cancer types have inspired the possible treatment
of patients with MI-BC with similar adjuvant agents [2]. For muscle-
invasive bladder tumors FGFR3 targeted therapy is being considered
[3,4,5,6] and recently a Phase II study has started to investigate the
efficacy of TKI258, an FGFR3 inhibitor, in patients with advanced
urothelial cancer (www.ClinicalTrials.gov NCT00790426). Like-
wise, the epidermal growth factor receptor (EGFR) is frequently
overexpressed in bladder cancer and might therefore be an
important therapeutic target for MI-BC [7,8,9]. Currently, EGFR
targeted treatment is being investigated for bladder cancer in several
clinical trials (CALBG-90102, NCT00088946, NCT00380029).
However, it has recently become clear that therapies targeting
receptor tyrosine kinases might not be effective when tumors harbor
mutations in the RAS-MAPK or PIK3CA-AKT pathways down-
stream of the receptors [10,11,12,13,14]. Nevertheless, agents
inhibiting targets downstream in these pathways are in clinical trials.
This suggests that screening bladder tumors for mutations in genes
such as FGFR3, RAS and PIK3CA can be of importance for future
therapy decisions. An easy test that can be implemented in the clinic
will therefore be desirable.
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For non-muscle-invasive bladder cancer (NMI-BC), the major
problem is that after initial transurethral resection of the bladder
(TURB), 50–70% of the patients develop multiple recurrences,
with a chance of 10–20% that these will progress to MI-BC
[15,16,17]. The recurrence risk and risk of progression necessitate
a life-long follow-up by cystoscopy. The current standard is to
perform a cystoscopy together with urine cytology every 3–4
months in the first 2 years and twice per year thereafter [18]. We
have recently shown that in the Netherlands patients with NMI-
BC undergo on average 20 cystoscopies during the first 9 years of
follow-up [17], with a recurrence detected in only one of seven of
these follow-up moments. For the USA and Europe with
populations of 300 and 450 million, this would amount to 1 and
1.5 million cystoscopies yearly. Reduction of the number of
cystoscopies by, for instance, a urine-based test is an important
goal in order to improve quality-of-life [19,20,21]. In addition, it
could lead to cost-reduction. Currently, bladder cancer is the most
expensive cancer type for treatment per patient [22,23]. However,
cytology and many of the currently developed urine biomarkers
have limited sensitivity for detection of low stage and grade tumors
that form the main group that recur (reviewed in [24,25,
26,27,28]).Therefore, there is a need for more sensitive urinary
biomarkers that can be implemented into molecular diagnostic
laboratories.
NMI-BC and MI-BC are genetically different [29,30]. NMI-BC
tumors are characterized by a high frequency of mutations in the
FGFR3 oncogene [31,32] leading to constitutive activation of the
RAS-MAPK pathway [33,34,35,36,37]. In MI-BC, mutations in
the TP53 gene prevail. Mutations in FGFR3 and TP53 are largely
mutually exclusive suggesting that NMI-BC and MI-BC develop
along different oncogenesis pathways [38,39]. However, in stage
pT1 tumors that invade the connective tissue layer underlying the
urothelium, they often occur together [32,38,39]. Recently,
somatic mutations in the PIK3CA oncogene, which encodes the
catalytic subunit p110a of class-IA PI3-kinase, were described in
13–27% of bladder tumors [40,41]. These mutations often
coincided with FGFR3 mutations. Mutations in the RAS oncogenes
(HRAS, KRAS, NRAS) have also been found in 13% of bladder
tumors and occurred in all stages and grades [41,42]. They were
mutually exclusive with FGFR3 mutations. However, no data exist
regarding the prognostic value, in terms of recurrence-free,
progression-free and disease-specific survival, of RAS and PIK3CA
mutations in bladder cancer either alone or in combination with
other alterations. In some cancer types PIK3CA mutations have
been associated with invasiveness and a worse prognosis
[11,43,44,45,46]. On the other hand, there are examples of
somatic mutations in benign skin lesions that do not progress
[47,48]. Regarding alterations in RAS and prognosis, in the past
studies have been performed on the prognostic value of expression
of RAS p21 protein, however the results were not concordant
[49,50,51]. A recent study on the expression of HRAS in 48 pTa
bladder tumors showed an inverse correlation of expression value
with recurrence and progression [52]. However, there is no
information on the prognostic value of mutations in the three RAS
genes in bladder cancer.
We have recently shown that with FGFR3 mutation analysis on
urine samples from bladder cancer patients it was possible to
detect recurrent tumors [53,54]. The technical performance of the
FGFR3 mutation assay in these studies was excellent. Sixty-three
percent of patients with NMI-BC are mutant for FGFR3. An
additional goal of the present study was to investigate whether
adding RAS and PIK3CA mutation analysis to the FGFR3 mutation
detection could potentially increase the percentage of patients that
can be monitored using urine-based assays for these mutations. In
addition, these assays could be of use in clinic to define patients
who may benefit from targeted therapies. We have therefore
developed a multiplex mutation assay for the detection of the most
frequently occurring HRAS, KRAS, and NRASmutations in bladder
cancer. This assay is based on assays that we previously developed
[53,55,56]. In our experience, these assays are sensitive, easy to
perform and to interpret, and require only a few nanograms of
DNA. The assays are also successful on DNA from formalin-fixed
paraffin embedded (FFPE) tissue or urine [53,54,56].
We subsequently investigated the mutation spectrum of FGFR3,
HRAS, KRAS, NRAS and PIK3CA in a large series of primary
tumors of 257 patients with NMI-BC and MI-BC. Mutation status
was also compared with p53 expression. The distribution of
alterations in these six genes together has not been investigated in
bladder tumors before. We further screened 184 recurrences of 54
patients to determine whether mutation status is consistent in
recurrences with the purpose to examine if it is useful to start a
longitudinal study on surveillance with these mutation assays for
the detection of recurrent bladder cancer in voided urine
specimens from patients. The frequency of mutations in RAS
and PIK3CA in a longitudinal setting containing multiple
recurrences of the same patient has also not yet been investigated
before.
We conclude that the mutation assays present a companion
diagnostic to stratify patients with MI-BC for targeted therapies. In
addition, since 88% of the primary tumors of patients presenting
with low-grade NMI-BC carried a mutation in the FGFR3, RAS,
and/or PIK3CA genes and 88% of the recurrences were mutant,
the assays are a potential tool to detect recurrences in DNA
obtained from urine samples during surveillance, which may
contribute to a reduction in the number of cystoscopical
examinations and is worth to investigate.
Methods
Patient characteristics and ethics statement
Formalin-fixed paraffin embedded (FFPE) samples of primary
tumors of an unselected group of 257 patients were obtained from
Erasmus MC and St Franciscus Gasthuis, Rotterdam, the
Netherlands. The tumor samples represent a subgroup of 286
samples that we previously described [32]. No tissue was available
anymore for the 29 missing samples. The mean age of this group
of patients at diagnosis was 65.7 years and male/female ratio was
3/1. Tumors were staged according to the Tumor Node
Metastasis classification of 1997 [57] and grades were classified
according to the World Health Organization criteria of 1973 [58].
Among the primary tumors, there were 166 pTa, 57 pT1, and 34
pT2-4 tumors. The grade distribution was 84 grade 1, 117 grade 2
and 56 grade 3 tumors. Of 54 patients that were treated at
Erasmus MC and had developed one or more recurrences,
formalin-fixed paraffin embedded tissue was collected from 184
consecutive recurrences. Clinical data of the tumors were obtained
from patient’s case history. Data were analyzed anonymously.
FFPE samples were used according to the standards presented in
‘‘The Code for Proper Secondary Use of Human Tissues in the
Netherlands’’ (http://www.federa.org/). Informed consent was
therefore not needed to be obtained. This was approved by our
Institutional Review Board. A recurrence was defined as a tumor
removed at transurethral resection that subsequently was con-
firmed to be tumor tissue by a pathologist. Tumors removed
within three months after transurethral resection were not
considered a recurrence. Progression was defined as progression
in stage and/or to grade 3. Disease-specific survival was defined as
time from diagnosis to death of bladder cancer. Follow-up period
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was counted from the date of diagnosis. Censoring of patients
occurred at their last clinical visit or when a patient died.
Generally, the patients were followed and treated according to the
guidelines of the European Association of Urology [18]. The
medical-ethical committee of the Erasmus University and the
University Hospital Rotterdam approved the study (METC
168.922/1998/55).
DNA isolation and mutation analysis
Haematoxylin-eosin stained slides were used for histological
diagnosis and served as templates for manual micro dissection
from the respective tissue blocks. The dissected tumor samples
contained a minimum of 70% tumor cells. Tumor samples were
extracted from Formalin-fixed paraffin embedded tumor tissue by
de-waxing with xylene and ethanol. DNA was isolated using
DNeasy Tissue kit (Qiagen, Hilden, Germany), according to the
protocol. P53, MIB-1 and p27Kip1 immunostaining was obtained
from van Rhijn et al. [32].
Primers for the multiplex RAS-BC assay were designed in such
a way that the single strands of the PCR products contained as
little potential secondary structure as possible in order to
facilitate efficient annealing of the mutation detection probes.
Primer design was further aimed at achieving identical annealing
temperatures to allow simultaneous amplification of the relevant
exons of the three RAS genes in one PCR reaction. Furthermore,
the regions to be amplified were inspected for the presence of
polymorphisms in the database of National Center for Biotech-
nology Information. No polymorphisms in these regions were
observed. Mutation detection probes for multiplex detection of
HRAS, KRAS and NRAS mutations were designed to anneal to
either the forward or the reverse strand directly adjacent to the
potential mutation site. With the assay, 19 possible mutations in
10 codons in the 3 RAS genes can be detected. Together they
account for 96% of all somatic HRAS, KRAS and NRASmutations
found in urothelial cell carcinomas by the Sanger Institute (www.
sanger.ac.uk/genetics/CGP/cosmic). To enable to distinguish
the probes by size, poly(dT) tails of different lengths were added.
All probes were designed to have similar annealing temperatures
and were selected for the absence of secondary structures and
base pairing with other probes. Primer and probe sequences and
concentrations for the three multiplex mutation assays for
FGFR3, NRAS, HRAS, KRAS and PIK3CA are depicted in
Figure 1 and 2.
Each multiplex PCR reaction was performed in a total volume
of 15 ml containing 0.17 mM dNTPs (Roche, Basel, Switzerland),
1.5 mMMgCl2, 5% glycerol (Fluka, Buchs SG, Switzerland), 0.3–
1.2 mM of the appropriate primer combination (Invitrogen,
Carlsbad, CA), 16 PCR buffer, and 0.5 units of Go Taq DNA
polymerase (Promega, Madison, WI), using 5 ng genomic DNA as
template. Thermal cycling consisted of initial denaturation at 95uC
for 5 min, followed by 35 cycles of each 95uC for 45 sec, 55uC for
45 sec, and 72uC for 45 sec. The final elongation step was 72uC
for 10 min. Unincorporated primers and deoxynucleotide triphos-
phates were removed from PCR products by addition of 2 units
Exonuclease I (ExoI) and 3 units shrimp alkaline phosphatase
(SAP, USB, Cleveland, Ohio USA).
PCR products were subsequently analyzed for mutations using
probes for each of the possible mutation sites and the SNaPshotH
Multiplex Kit (Applied Biosystems, Foster City, CA). The
mutation detection reactions were performed in a total volume
Figure 1. Primers used for multiplex amplification of HRAS, KRAS, NRAS, PIK3CA, and FGFR3.
doi:10.1371/journal.pone.0013821.g001
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of 10 ml containing 2.5 ml of SNaPshot Multiplex Ready
Reaction Mix, 2 ml BigDye sequencing buffer, 1 ml of probe
mix and 1 ml of SAP/ExoI treated PCR product. Extension
reactions consisting of 25 cycles of denaturation at 96uC for
10 sec and annealing/extension at 58.5uC for 40 sec, were
performed in a thermal cycler. After extension, the excess of
labeled dideoxynucleotide triphosphates was removed by treat-
ment with 1 unit shrimp alkaline phosphatase at 37uC for 60 min
and 72uC for 15 min. Extended primers were denatured at 95uC
for 5 minutes and separated by capillary electrophoresis on an
automatic sequencer (ABI PRISM 3130 XL Genetic Analyzer,
Applied Biosystems, Foster City, CA), and the presence or
absence of a mutation was indicated by the fluorescent label on
the incorporated nucleotide. Details of colors of the mutant and
wild-type peaks are given in Figure 2. Data were analyzed using
GeneScan Analysis Software version 3.7 (Applied Biosystems)
and GeneMarker Software version 1.7 (SoftGenetics LLC, State
College, USA).
Statistical analysis
Statistical analyses were performed using SPSS statistical
package (version 15.0, SPSS, Inc., Chicago, IL, 2003). Differences
were considered significant if p,0.05. The relationships between
mutation status and pathological and clinical variables were
analyzed by the Student’s t-test, Chi-square test and two-sided
Fisher exact tests. Recurrence-free, progression-free, and disease-
specific survival by mutational status was analyzed using Kaplan-
Meier curves. The two-sided log-rank test was performed to
compare the curves.
Results
Bladder cancer specific RAS-BC mutation assay
Somatic mutations in the HRAS, KRAS and NRAS genes in
bladder cancer affect codons 12, 13 and 61. In order to facilitate
detection of RAS mutations we have developed a multiplex RAS-
BC mutation assay that screens for 19 mutations simultaneously,
representing 96% of all possible known mutations in the 3 RAS
genes in bladder cancer (www.sanger.ac.uk/genetics/CGP/cos-
mic). The assay requires only a few nanograms of DNA and works
well on DNA from formalin fixed tissue. Figure 3 shows examples
of the RAS-BC assay with panel A representing the wild-type
situation and with specific mutations depicted in panels B–D.
Mutations in primary tumors
With the RAS-BC assay and mutation assays for FGFR3 and
PIK3CA, we screened primary bladder tumors of 257 patients for
mutations (Figure 4A). Overall, 64% (164/257) of the tumors
contained an FGFR3 mutation, a total of 28 (11%) samples were
mutant for one of the RAS genes and 61 (24%) harbored a PIK3CA
mutation. Table 1 shows the type of the identified mutations. The
most frequent RAS mutations were KRAS G12D and HRAS Q61R.
KRAS andHRASmutations occurred with equal frequency, whereas
NRAS mutations were not frequent in bladder cancer. In the
PIK3CA gene, the mutations occurred mostly in the helical domain
codons E545K and E542K. Overall, 18% (11/62) of the PIK3CA
mutations had occurred in the kinase domains and 82% in the
helical domains. We did not detect the alteration E545A indicative
for a polymorphism in the PIK3CA pseudogene of which the
Figure 2. Probes for the detection of HRAS, KRAS, NRAS, PIK3CA and FGFR3 mutations.
doi:10.1371/journal.pone.0013821.g002
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function is unknown [59]. In three primary tumors, two different
FGFR3 mutations were present (S249C together with A393E,
G372C or R248C). One primary tumor contained two different
PIK3CA mutations in the helical domains (E542K and E545K).
There was no obvious co-occurrence or mutual exclusiveness
between the different types of RAS and PIK3CA mutations.
Figure 3. RAS-BC mutation assay. Panel A: wild-type sample, panels B–D: samples with mutations. Position of the interrogated codons,
nucleotides and genes is depicted at the bottom.
doi:10.1371/journal.pone.0013821.g003
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The primary tumors were subsequently stratified into three
subgroups based on stage and grade; low-grade NMI-BC tumors
(pTaG1-2 and pT1G2), high-grade NMI-BC (pTaG3 and
pT1G3), and muscle-invasive tumors ($pT2). In Figure 4B–D,
the distributions of FGFR3, PIK3CA and RAS mutations in these
subgroups are illustrated. In the pTa-T1G1-2 group 88% of the
primary tumors harbor a mutation in at least one of the five
investigated oncogenes. Screening for PIK3CA and the three RAS
genes increased the percentage mutant tumors with 10% when
compared with FGFR3 alone. In the grade 3 and muscle-invasive
tumor groups, the total percentage of mutations in the
oncogenes is much lower with 33% and 36%, respectively. In
grade 3 tumors, the proportion of RAS mutations is relatively
large, whereas PIK3CA mutations are more prominent in the
muscle-invasive tumors. The addition of PIK3CA and RAS assays
results in the detection of 13% additional mutant primary
tumors in the grade 3 group and 15% in the muscle-invasive
group.
Co-occurrence of mutations
Of the 257 primary tumors, 26% had overexpression of p53,
which is indicative of missense mutations. When we combine the
oncogene mutations with those in the TP53 tumor suppressor gene
(Table 2), it appears that only 27 tumors (11%) were wild-type for
all examined genes. There were 9 primary tumors with a co-
Figure 4. Frequencies of FGFR3, PIK3CA and RASmutations in primary bladder tumors of 257 patients. Frequencies in all primary bladder
tumors (A) (n = 257) and in specific tumor stages: pTa/T1-G1/G2 (B) (n = 194), pTa/T1G3 (C) (n = 29) and muscle-invasive tumors (D) (n = 34).
doi:10.1371/journal.pone.0013821.g004
Table 1. Frequencies of individual mutations in primary
tumors of 257 patients.
FGFR3 gene N RAS genes N PIK3CA gene N
R248C 14 HRAS G12C 1 E542K 15
S249C 112 HRAS G12V 3 E545G 4
G372C 7 HRAS G13R 2 E545K 31
Y375C 27 HRAS Q61L 3 E545Q 1
A393E 1 HRAS Q61R 5 H1047L 4
K652M 2 KRAS G12C 3 H1047R 7
KRAS G12D 7
KRAS G12V 3
NRAS Q61L 1
doi:10.1371/journal.pone.0013821.t001
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occurrence of 3 alterations. There was a positive association of
mutant FGFR3 with PIK3CA mutations (p= 0.016), with 77% of
the PIK3CAmutations co-occurring with FGFR3 (Figure 5). FGFR3
mutations were strongly mutually exclusive with RAS mutations
(p= 0.001). Only 3.5% of the primary tumors contained a
mutation in both genes. Interestingly, the mutual exclusiveness
of FGFR3 and RAS mutations remained significant in the subgroup
of pTa/T1 G1/2 primary tumors, whereas PIK3CA and FGFR3
mutations are significantly co-occurrent in grade 3 tumors. Both
FGFR3 and PIK3CA mutations were mutually exclusive with p53
overexpression (p,0.001 and p= 0.029, respectively). RAS muta-
tions were not mutually exclusive with PIK3CA and p53 mutations
in the total cohort, nor in different tumor stage and grade
subgroups.
Correlations of mutations with stage, grade
We subsequently investigated the relation between stage and
grade and the different mutations (Figure 6). In primary tumors
there was a significant correlation of FGFR3 with low stage and
grade and a correlation of p53 overexpression with high stage and
grade, as shown previously [39]. However, no significant
association was observed between RAS mutation status and stage
or grade. The distribution according to stage was 10% pTa (16 of
166), 18% pT1 (10 of 57), and 6% muscle-invasive tumors (2 of
34). Regarding PIK3CA, the prevalence of mutations was higher in
low-grade tumors: 30% grade 1 (25 of 84), 23% grade 2 (27 of
117), and 16% grade 3 (9 of 56), however this association was not
statistically significant (p = 0.061). No correlation with stage was
observed.
Prognostic value
Fifty-nine percent (154/257) of the patients in our study
developed one or more recurrences, 10% had progression in stage
and/or to grade 3, 19% died of disease. None of the investigated
alterations in FGFR3, RAS, PIK3CA and p53 in the primary tumor
was a predictor for development of a recurrence (recurrence-free
survival p.0.05). Mutation frequency of PIK3CA in patients with
recurrences was similar compared to patients without recurrences
24% (37/154) versus 23% (24/103). For RAS mutations, these
frequencies were 12% and 10%. There was also no relation
between the mutation status of RAS and PIK3CA and recurrence
rate. As we showed previously, patients with an FGFR3 mutant
primary tumor have a lower risk of progression and a better
disease-specific survival, whereas patients with p53 overexpression
have high risk of progression and low disease-specific survival
[32,39]. However, PIK3CA or RASmutations were not significantly
associated with progression (p= 0.129, p= 0.694) or disease-
specific survival (p= 0.205, p= 0.447) in the entire cohort, nor
in different tumor stage and grade subgroups. Combining RAS and
PIK3CA mutation status provided similar results. Furthermore,
adding RAS or PIK3CA mutation status to FGFR3 or p53 did not
result in a better prediction of recurrence-free, progression-free or
disease-specific survival compared to FGFR3 or p53 alone. There
were also no significant correlation of individual RAS isoforms and
PIK3CA mutations in helical or kinase domains with stage, grade
Figure 5. Relations between mutations in primary bladder tumors of 257 patients.
doi:10.1371/journal.pone.0013821.g005
Table 2. Combinations of mutations in primary bladder
tumors of 257 patients.
Altered genes Number Percentage
FGFR3 97 37.7
FGFR3 + p53 14 5.4
FGFR3 + PIK3CA 39 15.2
FGFR3 + RAS 6 2.3
FGFR3 + p53 + PIK3CA 5 1.9
FGFR3 + RAS + PIK3CA 3 1.2
PIK3CA 6 3.1
RAS 9 3.5
RAS + PIK3CA 4 1.6
p53 + PIK3CA 3 1.2
p53 + RAS 5 1.9
p53 + RAS + PIK3CA 1 0.4
p53 38 14.8
wild-type 27 10.5
Total 257 100
doi:10.1371/journal.pone.0013821.t002
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or recurrence-, progression-, and disease-specific survival. Fur-
thermore, no significant correlation was found between RAS or
PIK3CA mutations and altered Ki-67 (p= 0.413, p= 0.227) or
p27Kip1 (p = 0.126 and p= 0.580) expression, markers indicative
for a worse prognosis in bladder cancer [60,61].
Frequencies of mutations in recurrences
From 54 patients that were treated at Erasmus MC and had
developed one or more recurrences, tissue was available of 184
recurrences (including multifocal recurrences). Here, we wanted to
investigate if mutation status persists in multiple recurrences of the
same patients with the purpose to examine if it is valuable to start a
future longitudinal study on surveillance with the mutation assays
by analyzing urine samples. We only examined mutation status of
the genes for which we have developed the SNaPshot based
mutation assay (i.e. FGFR3, PIK3CA and RAS). P53 overexpression
was not determined in recurrences. The frequency of p53
overexpression was also low (6/54) in the primary tumors of this
group of patients consisting mainly of NMI-BC tumors. A detailed
overview of stage, grade and mutation status of these tumors is
presented in Figure 7. In patients with a wild-type primary tumor,
recurrences were mostly wild-type (49/54 recurrences), while 5
harbored an FGFR3 mutation. One recurrent tumor contained
two different PIK3CA mutations (E542K and E545K). Interest-
ingly, in recurrences PIK3CA mutations in addition to an FGFR3
mutation was associated with higher grade compared to
recurrences harboring an FGFR3 mutation alone (p= 0.012). If
we stratify for patients with a mutant primary tumor, 81% of the
recurrences were also mutant and the individual frequencies were
75% (98/130) for FGFR3, 23% (30/130) for PIK3CA, and 10%
(13/130) for RAS. Interestingly, there was a 100% consistency in
the type of mutation for RAS and PIK3CA among different tumors
of the same patient. We earlier observed that some recurrences
were wild-type when the primary tumor was mutant for FGFR3
[17]. In the present study, there were 20 of 130 recurrences (15%)
in the patient subgroup with a mutant primary tumor that had
progressed to grade 3, CIS or muscle-invasive bladder cancer
(Figure 7). Of these, 90% (18/20) were mutant and therefore could
be detected with the mutation assay. The wild-type recurrences in
this patient group do not progress more often than the mutant
recurrences; 8% (2/25) of the wild-type recurrences had
progressed to CIS and to grade 3 (Figure 7), compared to 17%
mutant recurrences. One of these wild-type recurrences co-
occurred together with two mutant tumors. We further deter-
mined the time point at which the wild-type recurrences occurred
during follow-up. Most of the wild-type recurrences (18 of 25) co-
occurred together with a mutant recurrence or were later followed
by a mutant recurrence, whereas 7 occurred as wild-type alone at
the end of the follow-up period when no further data was
available.
One of the purposes of this study was to investigate if the
mutation assays are a potential tool for the detection of
recurrences in order to reduce the number of cystoscopical
examinations and whether it is useful to initiate a large
longitudinal study with these mutation assays for detection of
Figure 6. Frequencies of FGFR3, RAS, PIK3CAmutations and p53 overexpression according to stage and grade. The correlation of these
alterations in primary bladder tumors of 257 patients with stage (A) or grade (B) is indicated by p-values (x2).
doi:10.1371/journal.pone.0013821.g006
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recurrent bladder tumors using DNA extracted from urinary cells.
Patients that are eligible for such a follow-up are those that present
with a mutant pTaG1-2 or pT1G2 primary tumor. For this
subgroup of patients the frequency of mutations in the FGFR3,
PIK3CA and RAS genes when counted per recurrence event (i.e. in
case of multiple tumors removed at transurethral resection,
mutation data were combined) are illustrated in Figure 8. The
figure shows that in this group of patients a mutation is present in
88% of the recurrence events. This is an increase of 8% when
compared to FGFR3 alone.
Discussion
Activating point mutations in oncogenes present excellent
biomarkers for diagnostic assays and targets for therapy. In
urothelial tumors somatic mutations in the FGFR3, HRAS, NRAS,
KRAS and PIK3CA genes may be of use for early detection of
primary and recurrent tumors in urine-based assays, for prognosis
prediction, and as a companion diagnostic for targeted therapies.
In order to facilitate the detection of RAS mutations, we first
designed an assay that simultaneously investigates 19 possible
mutations in 10 codons of the 3 RAS genes. We used this bladder
cancer specific RAS-BC assay together with similar assays that we
developed previously for FGFR3 and PIK3CA [53,55], to
investigate the frequency of these mutations in an unselected
series of primary tumors of 257 patients representing all stages and
grades and 184 successive recurrent bladder tumors of 54 patients.
The frequency of RAS mutations in our study is similar to that
reported by others with different techniques [41,42]. KRAS and
HRAS mutations occurred with equal frequency. NRAS mutations
were not frequent in bladder cancer.
One of the main problems to address in bladder cancer is the
high recurrence rate and the need for efficient markers to detect
recurrences in a non-invasive way. Screening for the presence of
recurrences using urine-based assays can potentially improve
quality-of-life and reduce costs [19,20,21]. The SNaPshot based
mutation assays that we developed might be useful particularly for
urine analysis where only small amounts of DNA can be isolated
and the percentage of non-tumor cells may vary [53]. The assays
are also easy to perform, 100% reproducible, and inexpensive
(material costs amount under 10 dollar per analysis [56]).
Furthermore, the assays produce a positive signal, are easy to
interpret and interobserver agreement is very high. Therefore,
they are a suitable candidate for clinical implementation. We have
previously shown that FGFR3 mutation analysis on urine samples
from bladder cancer patients was able to detect recurrent tumors
[32,53,54]. Here we first investigated the frequency of patients that
could be eligible for follow-up based on mutation status of the
primary tumor. Furthermore, we investigated whether mutation
status is consistent in recurrent tumors of a patient with the
purpose to examine if it is useful to start a study on surveillance
with these mutation assays by analyzing urine samples in a large
longitudinal study. If the frequency of these mutations in
recurrences is low, it would not be useful to initiate such a study.
The addition of the RAS and PIK3CA assays increases the
percentage of low-grade NMI-BC patients to 88% for whom a
surveillance scheme that includes mutation analysis on urinary
cells could be of benefit. To determine whether mutation status is
consistent in recurrences, we further screened 184 successive
recurrences of 54 patients. In 88% of the transurethral resections
performed during follow-up, one or more recurrences were
mutant. Interestingly, there was a 100% consistency in the type
of mutation for RAS and PIK3CA among different tumors of the
same patient, which is in agreement with that the majority of
recurrences are considered to be clonally related [62,63,64]. This
homogeneity might be helpful in surveillance and therapy.
However, in 12% of the follow-up assays the recurrence could
not be detected with these assays. Nevertheless, the wild-type
tumors in a patient with a mutant primary tumor do not progress
very often and most of these wild-type tumors are later followed by
a mutant tumor. Hence, these wild-type recurrences could
potentially be detected in a later follow-up moment. An advantage
of the mutation assays is that with the assays it is possible to detect
mutant recurrences in the ureter and renal pelvis that cannot be
seen by cystoscopy as was shown for FGFR3 [65]. Cystoscopies are
often the standard to which the sensitivity of new urine based
biomarkers are compared. However the sensitivity of standard
white light cystoscopy is estimated to be 77–83% [66,67]. Hence,
for a future follow-up scheme a combination of frequent urine
assays and a reduced number of cystoscopies should be
investigated.
We further investigated the prognostic value in terms of
recurrence-free, progression-free and disease-specific survival of
the different mutations in primary tumors. In bladder cancer,
PIK3CA mutations had previously been associated with low grade
and stage tumors [40]. In our study PIK3CA mutations were
Figure 8. Frequency of mutations in recurrence events of
patients with a mutant pTa/T1G1/2 primary bladder tumor.
Frequency of FGFR3, RAS, and PIK3CA mutations is indicated.
doi:10.1371/journal.pone.0013821.g008
Figure 7. Detailed overview of the mutation status of 54 primary and 184 recurrent tumors. A: mutant primary tumors and their
recurrences; B: wild-type primary tumors and their recurrences. The first column indicates the primary tumor. The successive boxes indicate
temporally sequential recurrences removed in different transurethral resections (indicated by a sequence number on top). Multifocal tumors removed
at the same transurethral resection are positioned underneath each other. Stage and grade of the tumors, mutation status (indicated by a color) and
patient ID of the 54 patients is indicated.
doi:10.1371/journal.pone.0013821.g007
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equally frequent in pTa, pT1 and $pT2 tumors, however the
correlation of PIK3CA mutations with low grade was close to
significance (p= 0.061). There was no correlation between RAS
mutations and stage and grade of the tumor. Our results on a large
unselected series of consecutive tumors largely corroborate the
data obtained by others [40,41,42], although their tumor panels
were different, consisting of a relatively larger proportion of pTa
tumors [40] or grade 3 tumors [41]. In contrast to FGFR3 and p53
alterations, mutations in the RAS and PIK3CA genes were not
predictors for recurrence-free, progression-free and disease-specific
survival. There was also no difference in disease-specific survival
for RAS and PIK3CA mutations between invasive and non-invasive
groups.
The RAS-MAPK pathway and PI3K-Akt pathway are the two
most important molecular pathways involved in cell growth in
urothelial tumorigenesis [68,69]. Cross-talk between the two
signaling pathways can occur at several points and downstream
they may converge on mammalian target of rapamycin kinase
[70,71]. RAS proteins are able to activate Phosphatidylinositol 3
kinase (PI3K) through a direct interaction with p110a of PIK3CA
[72,73]. In activating p110a, HRAS has been shown to be the
most effective RAS isoform [74,75]. Oncogenic activation of RAS
genes can activate both Mitogen-activated protein kinases
(MAPK) and PI3K pathways [76]. In addition to RAS, upstream
FGFR3 is also able to activate both pathways. FGFR3 mutations
were mutually exclusive with RAS mutations in accordance with
their signaling through the same pathway in bladder cancer [37].
Interestingly, PIK3CA mutations generally co-occur with FGFR3
mutations suggesting an additive oncogenic effect of PIK3CA to
FGFR3 mutations. In our study, primary tumors harboring a
PIK3CA mutation in addition to an FGFR3 mutation were not
different in stage or grade compared to those containing an FGFR3
mutation alone. However, recurrences carrying both mutations
were significantly higher in grade.
There is accumulating evidence that the three different RAS
isoforms and helical and kinase domains of PIK3CA comprise
different functions [77,78,79], which also might explain the tissue
specific frequency of mutations. Recent functional assays showed
that, the helical domain mutant of PIK3CA can be activated by
RAS while the kinase domain mutant is not dependent on RAS
binding [77,79]. In breast cancer, mutations in the kinase domain
are of better prognostic value than mutations in the helical
domain, which might be explained by this synergy of RAS with
oncogenic helical domain of PIK3CA. We therefore compared
specific mutations in RAS isoforms and PIK3CA domains in
relation to prognostic factors. However, in our study mutations in
RAS isoforms and PIK3CA helical or kinase domains were not
significantly correlated with different stage and grade or
recurrence-free, progression-free, and disease-specific survival.
There was also no difference in frequency of mutations that co-
occurred with RAS mutations between helical and kinase domains
of PIK3CA.
FGFR3 targeted therapy is being considered for muscle-invasive
bladder tumors and recently a Phase II study has initiated in
patients with advanced urothelial cancer (NCT00790426). FGFR3
mutations are present in 21% of the MI-BC, and it was reported
that overexpression of the receptor occurs in almost 40% of MI-
BC [80]. This suggest that FGFR3 targeted therapy could be
useful for about half of the MI-BC patients. The assays presented
in this work could serve as a companion diagnostic to select
patients for such a therapy since mutations in the RAS and PIK3CA
genes, together amounting to 27% in MI-BC, might prohibit the
effect of FGFR3 inhibitors. For example in pre-clinical studies of
multiple myeloma, tumor cells are resistant to inhibition of the
Fibroblast Growth Factor Receptor 3 (FGFR3) in the presence of
a RAS mutation [12,13]. The assays may also be useful for future
therapies targeting the epidermal growth factor receptor (EGFR)
in bladder cancer, which are currently tested in clinical trials. For
advanced colorectal and lung cancers, patients currently are
screened for mutations in the KRAS gene as therapy targeting
EGFR is not effective when these tumors harbor mutations in the
pathway downstream of EGFR [10]. Because of the molecular
heterogeneity of bladder cancers, optimal targeted therapy will
require the combined use of inhibitors targeting multiple
molecular pathways [81,82]. With the current development of
small molecule inhibitors targeting receptor tyrosine kinases in the
MAPK and PI3K pathways, the detection of mutations will
become increasingly important to stratify patients.
The data presented here suggest that surveillance by mutation
analysis for FGFR3, PIK3CA and the RAS genes in combination
with extension of the period between cystoscopies could be a useful
follow-up strategy for those patients presenting with a mutant
NMI-BC, grade 1–2 primary tumor. However, the true value of
the mutation assays as biomarker for the detection of recurrent
bladder cancer in voided urine samples needs to be established in a
longitudinal study on patients under surveillance for recurrent
disease. The mutation assays may further be useful as a
companion diagnostic to define patients with MI-BC who may
benefit from therapies targeting FGFR3 or other receptors and
downstream targets.
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